+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2025-2030- Product Image
Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2025-2030- Product Image
Sale

Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924699
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Extensive Stage Small Cell Lung Cancer Market is rapidly evolving, shaped by therapeutic advancements, shifting regulatory climates, and supply chain pressures. Senior decision-makers seeking actionable intelligence and a view of tomorrow’s oncology landscape can leverage this report to inform investment, portfolio, and operational strategies.

Market Snapshot: Extensive Stage Small Cell Lung Cancer Market

The Extensive Stage Small Cell Lung Cancer Market grew from USD 5.40 billion in 2024 to USD 6.08 billion in 2025. It is expected to continue growing at a CAGR of 12.48%, reaching USD 10.94 billion by 2030. Key drivers include advances in immunotherapy, targeted drug development, new regulatory frameworks, and strengthened biopharmaceutical pipelines. Ongoing clinical innovation and regional policy changes continue to redefine the standard of care and market structure across major geographies.

Scope & Segmentation

This report provides a multi-dimensional analysis of the market, covering all critical segments, end users, and regional dynamics:

  • Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy
  • Chemotherapy Agents: Alkylating agents, Platinum complexes, Topoisomerase inhibitors
  • Immunotherapy Subtypes: CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors
  • Targeted Therapies: PARP inhibitors, Tyrosine kinase inhibitors
  • Distribution Channels: Hospital pharmacy, Online pharmacy, Retail pharmacy
  • End Users: Home healthcare settings, Hospitals, Oncology clinics
  • Mode of Administration: Intravenous, Oral
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific
  • Key Countries: United States (with state-level detail), Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland, China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan
  • Leading Companies: F. Hoffmann-La Roche AG, AstraZeneca PLC, Jazz Pharmaceuticals plc, RayzeBio, Inc., Amgen Inc.

Key Takeaways

  • The market is witnessing a shift as immunotherapy elevates the treatment paradigm, introducing new combination and sequencing approaches.
  • Innovations in supportive care and precision diagnostics are enabling more personalized treatment, reducing adverse effects and enhancing outcomes.
  • Growth in patient-centric administration modes, such as oral therapies and remote monitoring, is shaping delivery models and expanding access.
  • Strategic collaborations between pharmaceutical leaders and biotech innovators are accelerating late-stage research and pipeline diversification.
  • Regional variations in regulatory, reimbursement, and healthcare infrastructure require flexible, localized market entry and expansion strategies.
  • The growing emphasis on patient-reported outcomes is redefining value frameworks and influencing payer negotiation priorities.

Tariff Impact: Navigating the 2025 U.S. Policy Shift

New U.S. tariff policies instituted in 2025 have triggered changes across the oncology supply chain for small cell lung cancer treatments. Manufacturers are revising procurement strategies, expanding regional supply networks, and investing in domestic production to address rising duty rates on pharmaceutical ingredients and delivery devices. These shifts increase operational complexity and place new demands on cost control, inventory management, and partnership development with logistics providers and domestic suppliers. Proactive stakeholders are adopting analytics tools to mitigate risk, while providers balance incremental costs with uninterrupted patient access.

Methodology & Data Sources

This research is grounded in structured interviews with oncology and reimbursement experts, supplemented by expert panel validation and a rigorous review of peer-reviewed publications, clinical guidelines, and real-world data sets. Multi-tiered triangulation and cross-verification ensure unbiased insights tailored to the market’s complexity.

Why This Report Matters

  • Delivers a comprehensive, evidence-based guide for investment and portfolio planning in the evolving small cell lung cancer therapeutics sector.
  • Enables targeted strategic initiatives by detailing regional market entry challenges, technology innovation trends, and changing distribution models.
  • Supports informed negotiation and partnership strategies by clarifying how regulatory, supply chain, and value assessment drivers influence competitive positioning.

Conclusion

This report equips senior stakeholders with an in-depth, actionable view of the Extensive Stage Small Cell Lung Cancer Market. Timely insights provided here enable forward-looking organizations to navigate innovation, policy shifts, and regional complexities with confidence.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of novel immunotherapy combinations targeting PD-L1 and CTLA-4 pathways improving survival outcomes in ES-SCLC
5.2. Advancements in maintenance therapy protocols incorporating PARP inhibitors post first-line chemotherapy in ES-SCLC
5.3. Development and clinical integration of liquid biopsy assays for early detection of resistance in ES-SCLC treatment
5.4. Impact of real-world evidence on accelerated adoption of atezolizumab plus chemotherapy as first-line therapy in ES-SCLC
5.5. Application of next-generation sequencing panels enabling biomarker-driven personalized treatments in ES-SCLC patient populations
5.6. Clinical validation of DLL3-targeting antibody-drug conjugates offering new precision treatment options for ES-SCLC
5.7. Evolution of second-line therapy paradigms with oral lurbinectedin demonstrating improved tolerability and patient adherence in ES-SCLC
5.8. Increasing incorporation of patient-reported outcome measures in regulatory submissions for novel ES-SCLC therapies
5.9. Role of combination radiotherapy and immune checkpoint inhibitors in reducing incidence of brain metastases in ES-SCLC
5.10. Expansion of drug access through accelerated approval pathways in emerging markets for novel ES-SCLC treatments
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Extensive Stage Small Cell Lung Cancer Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Alkylating Agents
8.2.2. Platinum Complexes
8.2.3. Topoisomerase Inhibitors
8.3. Immunotherapy
8.3.1. Ctla-4 Inhibitors
8.3.2. Pd-1 Inhibitors
8.3.3. Pd-L1 Inhibitors
8.4. Targeted Therapy
8.4.1. Parp Inhibitors
8.4.2. Tyrosine Kinase Inhibitors
9. Extensive Stage Small Cell Lung Cancer Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Extensive Stage Small Cell Lung Cancer Market, by End User
10.1. Introduction
10.2. Home Healthcare Settings
10.3. Hospitals
10.4. Oncology Clinics
11. Extensive Stage Small Cell Lung Cancer Market, by Mode Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Americas Extensive Stage Small Cell Lung Cancer Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Extensive Stage Small Cell Lung Cancer Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Extensive Stage Small Cell Lung Cancer Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche AG
15.3.2. AstraZeneca PLC
15.3.3. Jazz Pharmaceuticals plc
15.3.4. RayzeBio, Inc.
15.3.5. Amgen Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET: RESEARCHAI
FIGURE 24. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET: RESEARCHSTATISTICS
FIGURE 25. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET: RESEARCHCONTACTS
FIGURE 26. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PLATINUM COMPLEXES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PLATINUM COMPLEXES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 93. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 96. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 97. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 98. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 99. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 100. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 101. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 110. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 111. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 112. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 113. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 114. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 115. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 180. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 181. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 182. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 183. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 184. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 185. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 186. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 187. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 194. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 195. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 196. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 197. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 198. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 199. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 200. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 201. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 222. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 223. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 224. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 225. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 228. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 229. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 238. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 239. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 240. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 241. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 242. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 243. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Extensive Stage Small Cell Lung Cancer market report include:
  • F. Hoffmann-La Roche AG
  • AstraZeneca PLC
  • Jazz Pharmaceuticals plc
  • RayzeBio, Inc.
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.08 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.94 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Non-Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 - Product Image

Non-Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Immuno-Oncology Market - Global Forecast 2025-2030 - Product Image

Immuno-Oncology Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
HER2 Non-Small Cell Lung Cancer Epidemiology Forecast 2025-2034 - Product Image

HER2 Non-Small Cell Lung Cancer Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) - Global Strategic Business Report - Product Image

Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) - Global Strategic Business Report

  • Report
  • 283 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.